IN VITRO DATA in Slovenian translation

• podatki in vitro
• podatkov in vitro
• podatke in vitro

Examples of using In vitro data in English and their translations into Slovenian

In vitro data have shown that at therapeutic concentrations,
Podatki in vitro kažejo, da ambrisentan pri terapevtskih koncentracijah ne zavira UGT1A1,

Based on in vitro data, riotsiguat and its main metabolite are found to be substrates for transport proteins P-gp(P-glycoprotein)
Glede na podatke in vitro je znano, da sta riociguat in njegov glavni presnovek substrata prenašalnih proteinov P-gp(P-glikoprotein)

Based on in vitro data, cinacalcet is a strong inhibitor of CYP2D6,
Na podlagi podatkov in vitro cinakalcet močno zavira CYP2D6,

In vitro data indicate that ceftolozane did not inhibit P-gp,
Podatki in vitro kažejo, da ceftolozan v terapevtskih plazemskih koncentracijah

Based on in vitro data riociguat and its main metabolite are substrates of the transporter proteins P-gp(P-glycoprotein) and BCRP(breast cancer resistance protein).
Glede na podatke in vitro je znano, da sta riociguat in njegov glavni presnovek substrata prenašalnih proteinov P-gp(P-glikoprotein) in BCRP(protein odpornosti na raka dojke).

In vitro data indicate that lipegfilgrastim is has little
Podatki in vitro kažejo, da lipegfilgrastim neposredno ali preko imunskega sistema le malo

You can use in vitro data to fully or partly fulfil information requirements that would otherwise need data to be generated with tests on living organisms(in vivo tests).
Podatke in vitro lahko uporabite za delno ali polno izpolnjevanje zahtev po informacijah, za katere bi se podatki v nasprotnem primeru morali pridobiti s testi na živih organizmih(testi in vivo).

In vitro data indicate that neither tazobactam nor the tazobactam metabolite M1 inhibit P-gp, BCRP, OATP1B1, OATP1B3,
Podatki in vitro kažejo, da niti tazobaktam niti njegov presnovek M1 v terapevtskih plazemskih koncentracijah ne zavirata prenašalcev P-gp,

In vitro data indicate that ulipristal acetate
Podatki in vitro kažejo, da ulipristalacetat

In vitro data indicated that idelalisib is not an inhibitor of the metabolising enzymes CYP1A2,
Podatki in vitro kažejo, da idelalizib ni zaviralec presnovnih encimov CYP1A2,

In vitro data show that CYP2C9, CYP2C19
Podatki in vitro kažejo, da so encimi CYP2C9,

In vitro data suggests that cysteamine bitartrate is likely to be metabolized by multiple CYP enzymes,
Podatki in vitro kažejo, da se cisteaminijev bitartrat verjetno presnavlja z različnimi encimi CYP, vključno s CYP1A2,

Although in vitro data suggest that efavirenz inhibits CYP2C9
Čeprav podatki in vitro nakazujejo, da efavirenz zavira CYP2C9

In vitro data also indicated that tafamidis meglumine does not significantly inhibit cytochrome P450 enzymes CYP1A2,
In vitro podatki so pokazali tudi, da tafamidis meglumin encimov citokroma P450 CYP1A2, CYP3A4, CYP3A5, CYP2B6,

Although in vitro data suggest that efavirenz inhibits CYP2C9
Čeprav in vitro podatki kažejo, da efavirenz zavira CYP2C9

In vitro data from human liver microsomes indicate that cytochrome P450 enzymes CYP2D6
In vitro podatki za človeške jetrne mikrosome kažejo, da sta pri tvorbi 8- hidroksi

The Applicant stated that the presented in vitro data can be predictive of pharmacokinetic bioequivalence for Cmax
Predlagatelj je izjavil, da lahko predstavljeni in vitro podatki nakazujejo na farmakokinetično biološko enakovrednost za Cmax

In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151.
In vitro podatki, pridobljeni na mikrosomih človeških ledvic, nakazujejo, da bi bile ledvice lahko eden pomembnejših organov za hidrolizo vildagliptina v njegov glavni neaktivni metabolit LAY 151.

a number of Member States did not consider the product to be approvable based on the submitted in vitro data only.
je več držav članic menilo, da zdravila ni mogoče odobriti zgolj na podlagi predloženih in vitro podatkov.

In vitro data showed no difference in plasma protein binding in plasma samples of healthy subjects and hepatically impaired(mild,
Podatki študije in vitro v plazemskih vzorcih niso prikazali razlik pri vezavi na beljakovine v plazmi med skupino zdravih oseb